tbuckley/cabot-search huggingface dataset:
Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients
Authors: Giacomo Coltro, Guadalupe Belen Antelo, Terra Lasho, Christy Finke, Animesh Pardanani, Naseema Gangat, Ryan M. Carr, Moritz Binder, Abhishek A Mangaonkar, David S Viswanatha, Rong He, Aref Al-Kali, Kebede H. Begna, Darci Zblewski, Mark Litzow, William J Hogan, Martin Fernandez-Zapico, Keith Robertson, Ayalew Tefferi, Mrinal M Patnaik
Journal: Blood (2019)
Demonstration of 99mTc-MDP Uptake in a Mobile Urinary Bladder Calculus on SPECT/CT
Authors: Molly B. Carnahan, Peter Hoang, William G. Eversman, Ming Yang
Journal: Clinical Nuclear Medicine (2019)

We report a large mobile bladder calculus with intense Tc-MDP uptake demonstrated on both whole-body bone scintigraphy and SPECT/CT images in a patient with complicated chronic history of urolithiasis and urinary tract infection. Bone tracer uptake in bladder calculus is a rare phenomenon and might be related to the composition and matrix of calculus, direct exposure to excreted radiotracer, and bacterial colonization on the surface of calculus.
ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL
Authors: Swagata Goswami, Chi-Ling Chiang, Kevan Zapolnik, Zhiliang Xie, James L. Lee, Sivasubramanian Baskar, Christoph Rader, John C. Byrd, Mitch A. Phelps, Bhavana Bhatnagar, Natarajan Muthusamy
Journal: Blood (2019)
Addition of the Anti-CD33 Monoclonal Antibody Mylotarg to Fludarabine/High Dose Cytarabine - Based Induction Significantly Improves Outcome in Patient Affected By FLT3-ITD Positive Cytogenetically Normal Acute Myeloid Leukemia
Authors: Paola Minetto, Anna Candoni, Fabio Guolo, Marino Clavio, Maria Elena Zannier, Maurizio Miglino, Maria Vittoria Dubbini, Enrico Carminati, Anna Sicuranza, Sara Ciofini, Elisabetta Tedone, Paola Contini, Clara Nurra, Monica Passannante, Filippo Ballerini, Antonia Cagnetta, Marco Gobbi, Monica Bocchia, Renato Fanin, Roberto Massimo Lemoli
Journal: Blood (2019)
Prothrombinase Induced Clotting Time Is More Sensitive then aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma
Authors: Debra Hoppensteadt, Emily Bontekoe, Fakiha Siddiqui, Ambar Farooqui, Omer Iqbal, Walter Jeske, Jeanine Walenga, Alfonso J Tafur, Jawed Fareed
Journal: Blood (2019)
IMMU-03. SUPPRESSION OF ONCOMETABOLITE 2-HYDROXYGLUTRATE PRODUCED BY MUTANT IDH1 GLIOMA WITH AGI-5198 ENHANCES THE EFFICACY OF RADIOTHERAPY AND IMMUNE CHECKPOINT BLOCKADE ELICITING IMMUNOLOGICAL MEMORY
Authors: Padma Kadiyala, Felipe Nunez, Maria Garcia-Fabiani, Fernando Nunez, Dan Li, Anna Schwendeman, Pedro Lowenstein, Maria Castro
Journal: Neuro-Oncology (2019)

Abstract Patients with mutant IDH1 gliomas survive ~3.8 year longer than patients harboring wildtype IDH1 glioma, irrespective of histology or genetic lesions, making mutant IDH1 an essential prognostic indicator. Mutant IDH1 gliomas are highly infiltrative with a high incidence of relapse. We are studying a low grade glioma subtype, genetically characterized by inactivating mutations in α-thalassemia/mental retardation syndrome X-linked (ATRX) gene, TP53 and gain of function mutations in isocitrate dehyrdogenase 1 (mIDH1). Mutation in IDH1 converts α-ketoglutrate (αKG) to 2-hydroxyglutarate (2HG), an oncometabolite that inhibits histone and DNA demethylases, leading to a hypermethylated tumor phenotype [1]. This leads to epigenetic reprograming of the tumor transcriptome. The role of 2HG as an immune regulator in the mIDH1 glioma tumor microenvironment remains to be elucidated. Herein, we investigate whether 2HG produced by mIDH1 glioma in the tumor microenvironment mediating antitumor immunity. We used mIDH1 inhibitor AGI-5198 to abrogate the neomorphic enzymatic activity of IDH1R132H in a transplantable mIDH1 glioma mouse model. Animals were implanted with mIDH1 tumor neurospheres and they were systemically administered with AGI-5198. Our results indicate that pharmacological inhibition of IDH1R132H enzymatic function significantly prolongs the median survival (MS) of mIDH1 glioma bearing mice (~1.5-fold vs controls); eliciting strong antitumor activity, eradicating 40% of the established mIDH1 gliomas. Our results also demonstrate that antitumor immunity induced by 2HG inhibition is enhanced when combined with standard of care (temozolomide and radiation) and anti-PDL1 immune checkpoint blockade. In addition, when the long-term survivors (&gt;90 days) were rechallenged with mIDH1 tumor cells in the contralateral hemisphere, without further treatment, all the mice remained tumor free, indicating the development of anti-glioma immunological memory. Collectively, these findings support the clinical testing of AGI-5198 as an adjuvant therapy and a novel immunotherapeutic strategy for treating patients with mIDH1 glioma.
Association of Anesthesia Care and Cognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia
Authors: Douglas A. Colquhoun, Michael R. Mathis
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Authors: Nadine Kutsch, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow, Ullrich Graeven, Jens Kisro, Alexander Kroeber, Eugen Tausch, Clemens-Martin Wendtner, Michael J. Eckart, Stephan Stilgenbauer, Xi Huang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst
Journal: Blood (2019)
Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)
Authors: Megan Melody, Sangeetha Gandhi, Zaid Abdel Rahman, Paula A Lengerke Diaz, Nicole Gannon, Allison C. Rosenthal, Tuan Truong, Mattia Novo, Eva Brandes, Gina Lange, Breanna Estby, Patrick Johnston, Stephen M Ansell, N. Nora Bennani, Jonas Paludo, Jose Villasboas, Ernesto Ayala, Han W. Tun, Hemant S. Murthy, Vivek Roy, James M. Foran, Januario E. Castro, Yi Lin, Mohamed A Kharfan-Dabaja
Journal: Blood (2019)
Treatment with Full Chemotherapy Regimens in Older Adults with Hodgkin Lymphoma Improves 3-Year Overall Survival, but Less Than Half Receive Full Regimens
Authors: Angie Mae Rodday, Theresa E. Hahn, Anita J Kumar, Peter K Lindenauer, Jonathan W. Friedberg, Andrew Matthew Evens, Susan K Parsons
Journal: Blood (2019)
Hodgkin's Disease
Authors: Philip Rubin
Journal: JAMA (1964)

There is a pervading pessimism in the literature and in clinical practice regarding the prognosis of Hodgkin's disease. Perusal of some of the widely studied textbooks of pathology presents the new generation of medical students with such statements as, "This disease is progressive and fatal," and "of hopeless outcome." This concept is being challenged by more and more clinical investigators. Easson<sup>1</sup>has recently written directly to the point of "cure" of Hodgkin's disease. Although he notes that this term is subject to much debate, and that few definitions can withstand criticism, he offers a realistic meaning: "Cure of a disease is taken to connote that in time—probably a decade or two after treatment—there remains a group of diseasefree survivors whose annual death rate from all causes is similar to that of a normal population group of the same sex and age distribution." Interest in Hodgkin's disease is much greater
Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience
Authors: James Yeung, Ashlea Campbell, Christian E Bryant, Liane Khoo, Scott Dunkley, Harry J Iland, Stephen R Larsen, Susan Moreton, Douglas E Joshua, Vinay Vanguru, Derek A McCulloch, Danny Hsu, John Gibson, P. Joy Ho, Christina Brown
Journal: Blood (2019)
INNV-17. INNOVATIVE EDUCATIONAL APPROACHES TO ENHANCE PATIENT AND CAREGIVER UNDERSTANDING OF TTFIELDS FOR GLIOBLASTOMA
Authors: Melissa Shackelford, Peggy Frongillo, Jeanine Certo
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION The most common, aggressive malignant brain tumor is Glioblastoma (GBM) with patient median survival of 15–21 months. Patients with GBM face devastation of diagnosis, disease-burden, and hardship of seeking accurate information regarding treatment options. Evolving technology-enhanced methods of learning challenge traditional ways patients with cancer are educated and create an educational paradigm shift. The device manufacturer of Tumor Treating Fields (TTFields)) has developed innovative supplementary educational platforms to compliment healthcare provider (HCP) education of patients-caregivers with GBM treated with TTFields. This report aimed to evaluate these supplementary educational platforms. METHODS Emerging technology methods were employed to address patient-caregiver frequently asked questions, which included queries regarding treatment overview, mechanism of action, treatment initiation, and management to potentially ease the emotional burden of patients-caregivers seeking TTFields information. The TTFields educational platforms included incorporation of Web program, Buddy Program, Open-House Program (live and webinar), Chalk-Talk Video, and Facebook. RESULTS Educational platforms connecting potential and current TTFields patients-caregivers via live/webinar Open-House events ensured patient support. The phone-based Buddy Program allowed for direct 1:1 discussions between potential and current TTFields patients-caregivers. Patient-caregiver surveys revealed 100% would recommend the program to others (n=91); 98% were satisfied with the call experience (n=90); 76% felt the most valuable takeaway was speaking to someone who understands their situation (n=82). Of ambassadors, 98% felt they helped address registrants’ concerns (n=150). A dedicated TTFields Facebook page and first-ever, industry-led Facebook Live event (national broadcast; patients-caregivers discussed unique issues) were launched. Additionally, vignettes (eg, videos, written stories) were shared through a dedicated patient-caregiver website and YouTube channel. CONCLUSIONS In an ever-growing information age, it is important that HCPs become aware of innovative ways to reach and provide education for patients with brain cancer. Emerging technology utilization may improve GBM supportive care, by improving communication channels and potentially easing burden.
GENE-20. IDENTIFYING POTENTIAL GENES AND MECHANISMS DRIVING IDH-MUTANT GLIOMA PROGRESSION AND RECURRENCE THROUGH RNA-SEQUENCING
Authors: Angela Cho, Amanda Hudson, Emily Colvin, Sarah Hayes, Helen Wheeler, Viive Howell
Journal: Neuro-Oncology (2019)

Abstract Gliomas are the most common primary brain tumors in adults. IDH-mutated low-grade gliomas of astrocytic lineage (astrocytomas) have a relatively indolent clinical course; however, over time they progress to a higher grade. Molecular studies revealed recurrent tumors harbor more mutations upon malignant progression when treated with chemotherapy and/or radiotherapy compared to treatment-naïve tumors. However, genes which promote progression and recurrence in these tumors are unknown. This study aims to identify the transcriptional drivers of progression and recurrence of IDH-mutant gliomas. Longitudinal comparison of transcriptional profiles was performed on 6 matched pairs of primary lesions and their higher-grade recurrent lesion collected 1 to 8 years later. Three patients received no treatment and three patients received radiotherapy alone between their first and second surgeries. RNA was extracted from frozen specimens and following quality control, analyzed with the Illumina Next-Generation Sequencing platform (HiSeq HT paired end, TruSeq Kit). Comparison of RNA-seq results from primary and recurrent specimens identified 2042 differentially expressed genes (FC ≥2) for the no-treatment group and 2066 differentially expressed genes for the radiotherapy group. These genes include CADM2, SPP1, NDRG2 and CA9 which are associated with pro-tumor processes such as signal transduction, cell adhesion and treatment resistance. Validation is in progress. Identifying key genes driving glioma progression and recurrence will increase our understanding of the nature of these tumors and reveal core processes and potential novel targets that may be exploited for additional therapies for this deadly cancer.
Level of Utilization and Provider-Related Barriers to Hydroxyurea Use in the Treatment of Sickle Cell Disease in Jos, Nigeria
Authors: Akinyemi Olugbenga David Ofakunrin, Kehinde Adekola, Edache Sylvanus Okpe, Stephen Oguche, Tolulope Afolaranmi, Patience Kanhu, Nantok Dami, Atiene Solomon Sagay
Journal: Blood (2019)
Post-Induction Minimal Residual Disease Measured By Flow Cytometry and Deep Sequencing of Mutant GATA1 Are Both Significant Prognostic Factors for Children with Myeloid Leukemia and Down Syndrome: A Nationwide Prospective Study of the Japanese Pediatric Leukemia/Lymphoma Study Group
Authors: Takashi Taga, Shiro Tanaka, Kiminori Terui, Shotaro Iwamoto, Hidefumi Hiramatsu, Takako Miyamura, Yoshiko Hashii, Daisuke Hasegawa, Hiroshi Moritake, Hideki Nakayama, Hiroyuki Takahashi, Akira Shimada, Tomohiko Taki, Tsutomu Toki, Etsuro Ito, Katsuyoshi Koh, Daiichiro Hasegawa, Asahito Hama, Akiko M Saito, Souichi Adachi, Daisuke Tomizawa
Journal: Blood (2019)
Acute Myeloid Leukemia (AML) Treated with Azacitidine: Survival Outcomes for Patients Who Complete More Than Six Cycles Are Similar to High-Risk Myelodysplastic Syndrome/Low Blast Count AML
Authors: Jill Fulcher, Zahra Abdrabalamir Alshammasi, Nathan Cantor, Christopher Bredeson, Grace Christou, Dawn Maze, Mitchell Sabloff, Jill Fulcher
Journal: Blood (2019)
Bortezomib: Once-Weekly 1.6mg/m2 Maybe a Better Choice Compared with Twice-Weekly 1.3mg/m2 in Newly Dignosed Multiple Myeloma
Authors: Yubin Li, Fangfang Li, Wangshan Song, Zhumei Zhan, Xiangxin Li, Lingling Wang, Fanglin Li, Ming Hou, Hao Li, Luqun Wang
Journal: Blood (2019)
Quality of care for breast cancer patients in Japan: An analysis of the Japanese Breast Cancer Registry
Authors: H. Mukai, T. Higashi, T. Iwase, T. Sobue
Journal: Journal of Clinical Oncology (2009)

6547 Background: In Japan, growing concern that patients do not receive optimum care led to the enactment of the Cancer Control Act in 2006, which mandates the government to undertake initiatives in ensuring the quality of cancer care. Here, we evaluated the current status of breast cancer care in Japan using process-of-care quality indicators (QIs) for breast cancer care. Methods: Combining clinical evidence and expert opinion, we developed 45 QIs covering the continuum of breast cancer care from initial evaluation to follow-up. Each QI describes standards of a particular aspect of care, and its score is calculated as the percentage of applicable patients who received the recommended care (adherence score). Of the 45 QIs, 7 could be scored using data in the Japanese Breast Cancer Registry, which covers about 40% of all Japanese breast cancer patients and has been continuously maintained since 1975. Results: The study population included 15,227 patients registered by 224 facilities in 2005. On average, patients received 72.1% of recommended care. However, substantial variation in adherence was seen across QIs (21–98%). Adherence score was less than 85% in five of seven QIs. Variation across facilities was observed in six QIs. Conclusions: The quality of breast cancer care in Japan has room for improvement in many aspects of care. Although the amount of data in the cancer registry suitable for quality assessment is limited, it is useful in detecting quality problems. [Table: see text] No significant financial relationships to disclose.
STAT3 Mutations and Anemia with Pure Red Cell Aplasia Are the Distinctive Features of T Cell Receptor Gamma Delta Type Large Granular Lymphocyte Leukemia
Authors: Taku Yamane, Toru Kawakami, Nodoka Sekiguchi, Jun Kobayashi, Toshimitsu Ueki, Hikaru Kobayashi, Sayaka Nishina, Kaoko Sakai, Hitoshi Sakai, Kazuo Oshimi, Yumiko Higuchi, Hideyuki Nakazawa, Fumihiro Ishida
Journal: Blood (2019)
Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
Authors: Abhishek Maiti, Caitlin R. Rausch, Jorge E. Cortes, Naveen Pemmaraju, Naval G. Daver, Farhad Ravandi, Guillermo Garcia-Manero, Gautam M. Borthakur, Kiran Naqvi, Maro Ohanian, Nicholas J. Short, Yesid Alvarado, Christopher B. Benton, Christopher B. Benton, Tapan M. Kadia, Koichi Takahashi, Musa E. Yilmaz, Nitin Jain, Steven M. Kornblau, Guillermo Montalban Bravo, Koji Sasaki, Michael Andreeff, Prithviraj Bose, Alessandra Ferrajoli, Ghayas C. Issa, Elias Jabbour, Lucia Masarova, Michael E. Rytting, Philip A. Thompson, Sa A Wang, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, Qi Zhang, Antonio Cavazos, Helen Ma, Carol A. Bivins, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, Sherry A. Pierce, Jing Ning, Wei Qiao, John S. Welch, Hagop M. Kantarjian, Marina Y Konopleva, Courtney D. DiNardo
Journal: Blood (2019)
Determining Resistance Mechanisms in BRAF-mutated Multiple Myeloma
Authors: Johannes M. Waldschmidt, Jake A. Kloeber, Tushara Vijaykumar, Antonis Kokkalis, Praveen Anand, Sayalee Potdar, Julia Frede, Monica S. Nair, Valeriya Dimitrova, Nikhil C. Munshi, Kenneth C. Anderson, Andrew J. Yee, Noopur S. Raje, Birgit Knoechel, Jens G. Lohr
Journal: Blood (2019)
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone
Authors: Maria-Victoria Mateos, Michele Cavo, Joan Bladé, Meletios A. Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ludek Pour, Mark Cook, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung-Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Maria Krevvata, Jianping Wang, Anupa Kudva, Jon Ukropec, Susan Wroblewski, Rachel Kobos, Jesús San-Miguel
Journal: Blood (2019)
Mapping the Road of Gvhd and GVT: A Longitudinal Study of Immune-Transcriptome Signatures As Novel Approach to Solve Post-Allogeneic Hematopoietic Cell Transplantation Dilemmas
Authors: Merav Bar, Alice Woo, Mohammed Toufiq, Sabri Boughorbel, Darawan Rinchai, Mohammed Elanbari, Valentina Mattei, Rebecca Mathew, Irene Cavattoni, Sabine Forer, Marco Zecca, Patrizia Comoli, Giovanni Grillo, Catherine Cole, Chiara Cugno, Sara Tomei, Damien Chaussabel, Sara Deola
Journal: Blood (2019)
Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis
Authors: Laura A Evans, Dragan Jevremovic, Bharat Nandakumar, Francis K. Buadi, Angela Dispenzieri, David Dingli, Martha Q. Lacy, Suzanne R. Hayman, Prashant Kapoor, Ronald S. Go, Nelson Leung, Amie Fonder, Miriam A. Hobbs, Yi L. Hwa, Eli Muchtar, Rahma M Warsame, Taxiarchis Kourelis, Stephen J Russell, John A. Lust, Yi Lin, Mustaqeem Siddiqui, Robert A. Kyle, Morie A Gertz, S. Vincent Rajkumar, Shaji K. Kumar, Wilson I Gonsalves
Journal: Blood (2019)
COMP-07. MACHINE LEARNING PREDICTS PROGRESSION AND SURVIVAL IN GLIOMA USING RADIOHISTOGENOMIC FEATURES
Authors: Jeffrey Traylor, Visweswaran Ravikumar, Arvind Rao, Ganesh Rao
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Random forest classifiers can predict survival and progression status with radiomic features. Here, we compare the predictions of radiomic, histomic, and genomic features on progression-free survival (PFS) and overall survival (OS) in patients with low-grade glioma (LGG). METHODS We identified patients from our institution and The Cancer Genome Atlas (TCGA) with LGG and analyzed histopathology, mRNA expression, and MRI sequences. Differential gene expression analysis was performed to obtain top gene expression values. Discriminative feature-oriented dictionary learning (DFDL)1 was used to extract histomic features from histopathology slides. Forty-four computer-derived texture features were extracted from segmented tumors for each MRI sequence. A random forest classifier with cross-validation was then used to evaluate binary predictions of PFS and OS using radiomic, genomic, and histomic features from institutional and TCGA data. RESULTS The out-of-bag (OOB) error rates for PFS and OS predictions from combined institutional and TCGA radiomic features (n = 104) was 0.22 and 0.15, respectively. Similarly, OOB error rates of PFS and OS predictions for institutional histomic features (n = 66) was 0.24 and 0.29, respectively. OOB error rates for predictions of PFS and OS from combined institutional and TCGA genomic features (n = 283) were 0.14 and 0.24, respectively. A combined model incorporating radiogenomic features from institutional and TCGA data performed slightly worse than either modality alone (PFS OOB error = 0.28, OS OOB error = 0.21), possibly due to fewer cases (n = 67). CONCLUSION Our findings indicate combining radiomic and genomic features can predict PFS and OS in patients with LGG. The utility of this methodology may help to predict malignant transformation in LGG. REFERENCES: Vu TH, Mousavi HS, Monga V, Rao G, Rao UA. Histopathological image classification using discriminative feature-oriented dictionary learning. IEEE transactions on medical imaging. 2015;35(3):738–51.